Industry Explores FDA Risk Classifications For Mobile Health Devices
The inherent connectedness of mobile health products makes FDA’s device accessory regulations increasingly difficult to interpret, according to the mHealth Regulatory Coalition.
More from Archive
More from Medtech Insight
A panel of regulatory pros offered stakeholders tips for avoiding FDA citations after facility inspections. The July 29 webinar, hosted by ProPharma and Hyman Phelps and McNamara, follows the agency’s May announcement that it plans to up random foreign inspections.
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Biostate AI has set up an Indian subsidiary, Bayosthiti, to develop cancer and cardiac diagnostics with local hospitals. This follows a joint venture with China's Kindstar Global and mirrors Biostate’s US collaboration with Mass General Brigham to build AI models for melanoma.